Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EPS Bio TechnologyROCO:4183 -3.52%70 FCF Margin % is 36.27% as of Jun. 2026, which is 1300% above its 10-year median of 2.59. GuruFocus rates ROCO:4183 with a GF Score™ of 70/100 and a GF Value™ of NT$18.34 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 813 Medical Devices & Instruments companies, EPS Bio Technology ranks worse than 55.47% on this metric.
The historical rank and industry rank for EPS Bio Technology's FCF Margin % or its related term are showing as below:
ROCO:4183'
s FCF Margin % Range Over the Past 10 Years
Min: -10.36 Med: 2.59 Max: 15.27
Current: -2.64
During the past 13 years, the highest FCF Margin % of EPS Bio Technology was 15.27%. The lowest was -10.36%. And the median was 2.59%.
ROCO:4183's FCF Margin % is ranked worse than 55.47% of 813
companies
in the Medical Devices & Instruments industry
Industry Median: -0.74
vs ROCO:4183: -2.64
The historical data trend for EPS Bio Technology's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4183 vs ABT, SYK, MDT: FCF Margin % Comparison
For the Medical Devices subindustry, EPS Bio Technology's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
EPS Bio Technology FCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, EPS Bio Technology's FCF Margin % distribution charts can be found below:
* The bar in red indicates where EPS Bio Technology's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EPS Bio Technology (ROCO:4183) has a FCF Margin % of 36.27% as of Jun. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on EPS Bio Technology and its competitors. This is 1300% above median its historical median of 2.59. According to the industry distribution chart, EPS Bio Technology ranks #451 out of 813 companies in the Medical Devices & Instruments industry, placing it in the top 55.5%.
Is EPS Bio Technology's FCF Margin % too high?
EPS Bio Technology's current FCF Margin % of 36.27% is 1300% above median its 10-year median of 2.59. Based on the distribution chart, EPS Bio Technology ranks #451 out of 813 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, EPS Bio Technology has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does EPS Bio Technology's FCF Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, EPS Bio Technology ranks #451 out of 813 companies for FCF Margin %. This places EPS Bio Technology in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Devices & Instruments company?
A good FCF Margin % depends on the Medical Devices & Instruments industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on EPS Bio Technology and its competitors. EPS Bio Technology's current FCF Margin % is 36.27%, which is 1300% above median its own 10-year median of 2.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EPS Bio Technology stock overvalued right now?
Based on GuruFocus' analysis, EPS Bio Technology (ROCO:4183) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$18.34, compared to a current price of NT$13.70 — trading 25.3% below its estimated fair value. The current FCF Margin % is 36.27%, which is 1300% above median its 10-year median of 2.59. EPS Bio Technology's overall GF Score™ is 70/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For EPS Bio Technology (ROCO:4183), the current FCF Margin % is 36.27% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is EPS Bio Technology (ROCO:4183) Overvalued in 2026?
Based on GuruFocus' analysis, EPS Bio Technology stock appears to be undervalued.
The current stock price of NT$13.70 is trading 25.3% below its estimated GF Value™ of NT$18.34.
GuruFocus considers EPS Bio Technology to be Modestly Undervalued.
Key valuation signals for ROCO:4183:
FCF Margin %: 36.27% (1300% above median its 10-year median of 2.59)
GF Value™: NT$18.34 vs. price of NT$13.70 (25.3% below fair value)
No single metric tells the full story. See the ROCO:4183 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
EPS Bio Technology Corp operates in medical equipment manufacturing, international trade, intellectual property, and research, design, development, manufacture and sale of blood glucose measuring system and cirrhosis testing system. Its products include Test sheet and Glucose machine. Geographically it operates in Germany, Iran, Kingdom of Saudi Arabia, Switzerland, Las Vegas, and Others with majority of the revenue deriving from Germany.
70GF Score
Get the complete analysis for ROCO:4183
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4183 has been successfully added to your 
